We're glad you found us!
Inflammation is a primary mechanism for many illnesses. The problem with inflammation is not how often it starts but how often it fails to subside.
Our website was created to provide information about resolving symptoms of autoimmune and other chronic inflammatory diseases with Inflammation Therapy. This novel therapy is based on the theory that non-resolving inflammation is caused by the immune system's futile attempts to eradicate an intracellular infection. Here is a short, basic explanation.
Cell wall deficient bacteria are known to invade nucleated cells and it appears they interfere with immune system function by down-regulating the vitamin D receptor (VDR). Thus, the sabotaged immune system is less capable of transcribing antimicrobial peptides (AMPs) which kill bacteria and other pathogens, allowing the parasitic bacteria to reproduce while hidden within the cells. Infected macrophages increase extra-renal production of 1,25(OH)2D (calcitriol) in an effort to up-regulate the VDR and eliminate the bacterial invaders. Production of cytokines and endotoxins also contribute to the end result which is persistent, low-grade inflammation, tissue damage and disease.
Elevated 1,25(OH)2D and low 25(OH)D (which is erroneously diagnosed as vitamin D deficiency) are diagnostic markers of this inflammatory process. For details and scientific references, please read our peer-reviewed paper published in Inflammation Research - Inflammation and vitamin D: the infection connection.
Inflammation Therapy is a type of activation immunotherapy designed to improve immune system function. Its key component is Benicar (olmesartan medoxomil), an angiotensin receptor blocker. Benicar is approved by the FDA for the treatment of hypertension in adults and children but is used off-label for Inflammation Therapy. Benicar appears to be a ligand of the vitamin D nuclear receptor (VDR) capable of agonizing (up-regulating) the VDR. As a result, production of antimicrobial peptides is increased which results in elimination of the offending intracellular bacteria and thus, eventual resolution of inflammatory symptoms.
Inflammation Therapy includes pulsed administration of low-dose oral antibiotics to weaken and help eradicate the intracellular pathogens. With each antibiotic dose, inflammatory symptoms (Jarisch-Herxheimer reaction) wax and wane, providing evidence of persistent infection. Changes in laboratory findings (e.g., BUN, creatinine, CRP, blood counts, liver enzymes) often point to areas of occult inflammation. A correlating treatment strategy is the avoidance of excessive sunlight exposure, foods high in vitamin D and vitamin D supplements, in order to maintain serum 25(OH)D at a level (20-30 ng/ml) that isn't likely to suppress the immune system and inhibit bacterial elimination.
Please click on 'Inflammation Therapy' in the navigation bar (to the left), to learn more.
Chronic Illness Recovery provides a counseling service for patients who are on Inflammation Therapy, with the authorization of their medical provider. Patients report weekly in a secure, online forum. A Registered Nurse responds to the patient's report to provide an assessment and guidance. In this way patients are assured that treatment is on track. Doctors receive the reports and responses via secure fax which allows them to monitor their patient's care and to obtain a written record for the patient's clinic file.
If you wish to enroll in our counseling program for patients on Inflammation Therapy, please email us at
We look forward to assisting you in any way we can.
Meg Mangin, RN
"Your help to me has been extraordinary! Thank you so much. I asked my doctor if the service CIR was providing was helpful. Her response was an immediate resounding, Thank you. It's so worthwhile." Sue from St. Louis
We invite you to join our mailing list for an informative monthly newsletter and notices of our Patient Workshops. Your email address will not be shared with anyone.
This site complies with the HONcode standard for trustworthy health information:
Updated April 27, 2015